Oyster Point Pharma, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
202 Carnegie Center, Suite 106, Princeton, New Jersey
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2022 - Nov 10, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 547 % -62.9%
Quick Ratio 21.2 %
Debt-to-equity 353 % +2364%
Return On Equity -490 % -881%
Return On Assets -108 % -148%
Operating Margin -422 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.8M shares +2.6%
Common Stock, Shares, Outstanding 26.8M shares +2.83%
Common Stock, Value, Issued 27K USD +3.85%
Weighted Average Number of Shares Outstanding, Basic 26.8M shares +3.05%
Weighted Average Number of Shares Outstanding, Diluted 26.8M shares +3.05%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 5.59M USD -68.8%
Revenue from Contract with Customer, Excluding Assessed Tax 37.5M USD
Cost of Revenue 4.52M USD
Research and Development Expense 18.7M USD -38.6%
Selling and Marketing Expense 103M USD +21.6%
General and Administrative Expense 52M USD +35%
Operating Income (Loss) -158M USD -98.2%
Nonoperating Income (Expense) -18.2M USD -214%
Net Income (Loss) Attributable to Parent -177M USD -119%
Earnings Per Share, Basic -6.65 USD/shares -113%
Earnings Per Share, Diluted -6.65 USD/shares -113%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 68.8M USD -62.6%
Accounts Receivable, after Allowance for Credit Loss, Current 13.2M USD
Inventory, Net 6.96M USD
Assets, Current 97.7M USD -48.5%
Property, Plant and Equipment, Net 2.44M USD +23.4%
Operating Lease, Right-of-Use Asset 2.44M USD +289%
Other Assets, Noncurrent 5.69M USD +116%
Assets 109M USD -44%
Accounts Payable, Current 4.15M USD +18.2%
Accrued Liabilities, Current 24.4M USD +118%
Liabilities, Current 29.2M USD +92.6%
Operating Lease, Liability, Noncurrent 1.79M USD +941%
Other Liabilities, Noncurrent 8.18M USD +3336%
Liabilities 131M USD +129%
Retained Earnings (Accumulated Deficit) -390M USD -82.8%
Stockholders' Equity Attributable to Parent -22.2M USD -116%
Liabilities and Equity 109M USD -44%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -49.7M USD -201%
Net Cash Provided by (Used in) Financing Activities -218K USD -212%
Net Cash Provided by (Used in) Investing Activities -85K USD +75%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 26.8M shares +2.83%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -50M USD -200%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 68.8M USD -62.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.07M USD
Operating Lease, Liability 2.47M USD +288%
Payments to Acquire Property, Plant, and Equipment 85K USD -75%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -36.7M USD -108%
Lessee, Operating Lease, Liability, to be Paid 2.72M USD +311%
Property, Plant and Equipment, Gross 2.75M USD
Operating Lease, Liability, Current 675K USD +45.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 646K USD +413%
Lessee, Operating Lease, Liability, to be Paid, Year One 792K USD +111%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 253K USD +912%
Lessee, Operating Lease, Liability, to be Paid, Year Three 562K USD +2576%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 525K USD
Additional Paid in Capital 368M USD +4.83%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 74K USD +222%
Share-based Payment Arrangement, Expense 15.4M USD +39.7%
Interest Expense 12.3M USD +211%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%